Results 41 to 50 of about 3,811,568 (245)

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

, 2013
BACKGROUND: Median overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) was 13-16 mo in the predocetaxel era. Prognostic nomograms for survival estimation in CRPC were constructed prior to the introduction of docetaxel
Pezaro, Carmel, Omlin, Aurelius, Thompson, Emilda, Sandhu, Shahneen, Maier, Gal, de Bono, Johann, Attard, Gerhardt, Bianchini, Diletta, Olmos, David, Ferraldeschi, Roberta, Parker, Chris, Mukherji, Deborah, Mulick Cassidy, Amy   +12 more
core   +1 more source

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. [PDF]

PLoS ONE, 2012
The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests that mitotic proteins may be rationally targeted at this lethal stage of the disease.
Kanishka Sircar, Heng Huang, Limei Hu, Yuexin Liu, Jasreman Dhillon, David Cogdell, Armen Aprikian, Eleni Efstathiou, Nora Navone, Patricia Troncoso, Wei Zhang   +10 more
doaj   +1 more source

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis [PDF]

, 2011
Background: Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics.
Eva Juengel, Hudak, Lukasz, Waaga, Ana Maria da Silva Rosa, Roman A Blaheta, Lukasz Hudak, Blaheta, Roman A., Igor Tsaur, Makarević, Jasmina, Haferkamp, Axel, Jens-Michael Seibel, Wedel, Steffen, Haferkamp Axel, Waaga-Gasser Ana, Seibel Jens-Michael, Juengel Eva, Blaheta Roman A, Makarević Jasmina, Waaga-Gasser, Ana, Jasmina Makarević, Axel Haferkamp, Wedel Steffen, Jüngel, Eva, Seibel, Jens-Michael, Ana Waaga-Gasser, Tsaur Igor, Juengel, Eva, Wedel, Steffen Alexander, Tsaur, Igor, Hudak Lukasz, Steffen Wedel   +29 more
core   +2 more sources

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2019
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial ...
Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R, for the ARAMIS Investigators, Aglietta, Massimo, Damiano, Rocco, Facchini, Gaetano, Gasparro, Donatello, Mucciardi, Giuseppe, Natoli, Clara, Sabbatini, Roberto, Scagliotti, Giorgio, Schepisi, Giuseppe, Serretta ,Vincenzo   +24 more
openaire   +3 more sources

Amplification of KCNMA1 : a potential therapeutic target in prostate cancer [PDF]

, 2007
Prostate cancer is the most common cancer in males and the second leading cause of cancer deaths in western countries. Although most prostate cancers initially respond well to androgen withdrawal, they become inevitably resistant to this treatment and ...
Bloch, Michael
core   +1 more source

Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy [PDF]

, 2011
Prostate cancer is a very important health problem in the UK and worldwide. Available treatments such as radiotherapy, surgery and androgen ablation have failed to significantly increase the life expectancy of prostate cancer patients.
Rivera Gonzalez, Guillermo C
core   +6 more sources

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Frontiers in Oncology, 2016
Historically, androgen-deprivation therapy was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer, there are a few life-prolonging drugs, including taxanes such as docetaxel
Masaki eShiota, Akira eYokomizo, Masatoshi eEto   +2 more
doaj   +1 more source

Re: The Role of MicroRNA in Castration-Resistant Prostate Cancer

, 2016
EDITORIAL COMMENT Castration-resistant prostate cancer (CRPC) arises when hormone refractory prostate cancer growth occurs in a castrate androgen level environment. Although the mechanism is not fully understood, the androgen receptor (AR) has emerged
Fehmi Narter
core   +1 more source

Darolutamide For Castration-Resistant Prostate Cancer.

OncoTargets and therapy, 2019
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone ...
Bastos,Diogo A, Antonarakis,Emmanuel S
openaire   +3 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source